라니비주맙: 두 판 사이의 차이

202 바이트 추가됨 ,  2022년 2월 16일 (수)
잔글
50번째 줄: 50번째 줄:
* [[SUSTAIN]]
* [[SUSTAIN]]
* [[PrONTO]] (Prospective OCT Imaging of Patients with Neovascular AMD Treated with intraOcular Ranibizumab)<ref>Fung AE et al. An OCT-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for wAMD. ''AJO''. 2007 Apr;143(4):566-83. [https://pubmed.ncbi.nlm.nih.gov/17386270/ 연결]</ref>
* [[PrONTO]] (Prospective OCT Imaging of Patients with Neovascular AMD Treated with intraOcular Ranibizumab)<ref>Fung AE et al. An OCT-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for wAMD. ''AJO''. 2007 Apr;143(4):566-83. [https://pubmed.ncbi.nlm.nih.gov/17386270/ 연결]</ref>
* [[HORIZON]]
* [[HORIZON]]<ref>Singer MA et al. HORIZON: an open-label extension trial of ranibizumab for CNV secondary to AMD. ''Ophthalmology''. 2012 Jun;119(6):1175-83. [https://pubmed.ncbi.nlm.nih.gov/22306121/ 연결]</ref>
* [[SECURE]]
* [[SECURE]]
{{참고}}
{{참고}}